市場調查報告書
商品編碼
1535246
止血檢驗市場:各市場區隔規模,佔有率,法律規章,償付,2033年為止的預測Hemostasis Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
止血篩檢測試有助於識別止血功能受損的患者。這些測試可以幫助預測手術期間的出血風險,並識別有過度瘀傷或出血史的患者的特定缺陷。這些測試也用於監測正在服用影響血液凝固的藥物(口服抗凝血劑或 Vit-k 拮抗劑)的患者。
凝血?原(PT)和活化凝血?原(aPTT)檢驗是最廣泛使用的止血檢驗。這些設備經常用於術前凝血測試。 PT 測試也常用於監測服用維生素 K 拮抗劑(如華法林、苯丙香豆素和醋硝香豆素)的患者。
本報告提供全球止血檢驗市場相關資料詳細考察,提供市場上競爭情形,SWOT分析,到2033年為止的市場預測,地區,各國的趨勢等資訊。
Hemostasis Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative and qualitative market trends within In Vitro Diagnostics therapeutic area.
Hemostasis screening tests help to identify patients with hemostatic defects. These tests helps to predict bleeding risk in surgeries and to identify specific defects in patients with a history of excessive bruising or bleeding. These tests are also used in monitoring patients who take medications (Oral anticoagulants or Vit-k antagonists) that affect clotting ability.
Prothrombin (PT) and Activated Prothrombin (aPTT) tests represent the most widely used Hemostasis tests. These devices are frequently utilized for coagulation testing prior to surgery. PT tests are also frequently used for monitoring of patients taking vitamin K antagonists such as warfarin, phenprocoumon, and acenocoumarol.
Each of the covered 39 countries color-coded and fully-sourced market models are equipped with epidemiology based indications. The interactive excel deliverable covers value, volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.
Key Inclusions of the market model are:
Currently marketed Hemostasis tests and evolving competitive landscape:
Global, Regional and Country level market specific insights:
Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.
Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.
Companies covered: Abbott Laboratories, Roche Diagnostics International Ltd, Siemens Healthineers AG, Diagnostica Stago SAS, Instrumentation Laboratory Co, Bio-Rad Laboratories Inc, bioMerieux SA, Quidel Corp, Radiometer Medical ApS, Tulip Diagnostics Pvt Ltd and others
Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.
This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -
The model will enable you to -